Royal North Shore Hospital’s nephrology department is spearheading 20 clinical trials with over 50 patients enrolled in 2024. But he stresses there is much more to do to improve outcomes for people with kidney disease. He is involved in the leadership of several international trials testing new medicines to reduce the risk of kidney failure in people with non-diabetic kidney disease and prevent cardiovascular complications in people receiving dialysis. Brendon’s dedication to clinical trials and his work with SGLT2 inhibitors exemplify the profound impact that rigorous scientific research can have on global health. “The research allowed us to better understand the effects of SGLT2 inhibitors on a range of important outcomes for different types of patients,” he says. Brendon is proud the work has had a global impact. “It has, in part, helped support the inclusion of SGLT2 inhibitors on the World Health Organisation List of Essential Medicines,” he says. The drug is now available in almost every country for less than a cup of coffee, and widely recommended in almost every major clinical practice guideline for patients with type 2 diabetes, kidney disease or heart failure.
11
Made with FlippingBook - professional solution for displaying marketing and sales documents online